Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmeterol/Fluticasone Easyhaler (SF Easyhaler) is a combination dry powder inhaler developed by Orion Corporation for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It delivers a fixed-dose combination of salmeterol xinafoate, a long-acting beta-2 adrenoceptor agonist (LABA) that provides sustained bronchodilation, and fluticasone propionate, a synthetic corticosteroid with potent anti-inflammatory action. In clinical pharmacology, "SF Easyhaler + charcoal" refers to the administration of the inhaler alongside activated charcoal. This protocol is specifically used in pharmacokinetic studies to block the gastrointestinal absorption of the swallowed portion of the inhaled dose, thereby allowing researchers to isolate and assess the pulmonary deposition and absorption of the active ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SF Easyhaler + charcoal.